Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Resverlogix Corp T.RVX

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s): RVXCF

Resverlogix Corp is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I.
Price: $0.71 | Change: $0.00 | % Change: 0.00%
Volume: 20,825 | Day High/Low: 0.72/0.71 | 52 Week High/Low: 3.83/0.15

View modes: 
0 stars

RE:RE:RVX share price

Biotech: Have you heard of  "Ipilimumab" marketed as Yervoy by bristol Myers, ...for late stage Melanoma..?? G1945V  rate and reply
5 stars

RE:RVX share price

I'm not sure what the rules are in Canada, but having been in this situation in the US more than once, the Reg FD disclosure rules really prevent any written disclosure of material that has not...read more
5 stars

RE:RVX share price

Do you really think that Dart or Don and any other major shareholder would be happy with .90 cents. Come on!!! Patrick is a young kid with little IR experience. He is given a script and follows said...read more
5 stars

RE:RE:RE:NISSEN INTERVIEW DURING. THIS MONTHS ACC

Hi Sanfran. I think Don said that the next trial for rvx-208 MACE was going to be done in Canada. This is why I suggested in a post a few weeks ago that perhaps they can achieve some Canadian R & D...read more
0 stars

Great article on new Diabetes technology I found interesting

New Diabetes Therapy to Replace Insulin Injections Sernova Cell Pouch(TM) Technology Re-Invents Traditional Diabetes Care       LONDON...read more
5 stars

RVX share price

Incredible posts today from GV, biotech and Sanfran and very positive toward rvx-208 overall. The reply from RVX toward Sanfran's questions struck me today (after some reflection) that they (the...read more
0 stars

RE:RE:RE:Dr. JJ

yes, and he is ALSO the current CEO of a competing company. It doesn't bother me as it shows he believes in the Apo/HDL hypothesis. I simply mentioned it as there are always way more perceived...read more
5 stars

RE:RE:Dr. JJ

Dr JJ is a senior officer of Resvelogix Corp., and presently holds 41,500 RVX common shares + 500,000 options (common shares) G1945V  rate and reply
0 stars

RE:Dr. JJ

Correction: It would be HMCS Resverlogix, not RMS Resverlogix.  Apologies!  rate and reply
4.5 stars

RE:Dr. JJ

I agree that the traget is very clear. This is not a difficult trial to design and execute which is why I do not yet expect any partnering deal. Just a straight raise to fund this trial. I also agree...read more
5 stars

Dr. JJ

And one more thing:  I have a feeling that Dr. JJ is going to blow the critics out of the water with the next RVX-208 human study. Just a hunch folks. Yup... I'm as much of a believer as I ever...read more
5 stars

RE:RE:RE:RE:RE:RE:NISSEN INTERVIEW DURING. THIS MONTHS ACC

All good points, Biotech.  And well reasoned. I stand by my comments nevertheless, as I think mine are also good points well reasoned!  ( : Regarding the dosing of the infusions being much stronger,...read more
5 stars

RE:RE:RE:RE:RE:INTERESTING REPORT FROM ACC PRESENTATION ON evolocumab :

Yep, that is exactly the question and the issue which is why I say that this therapy is going to be for theose who can not tolerate or do not respond to statins as what insurance company is going to...read more
5 stars

RE:RE:RE:RE:INTERESTING REPORT FROM ACC PRESENTATION ON evolocumab :

Biotech: Is it also true that evolocumab is for patients that cannot tolerate statins. And this method by way of an injection is extremely costly.  For those shareholders south of the border, will...read more
5 stars

RE:RE:RE:RE:RE:NISSEN INTERVIEW DURING. THIS MONTHS ACC

Apoa-1/ HDL still has a cloud hanging over its head in the scientific community. The Cerenis PII trial results released in January that failed to meet endpoints is case in point. So thats billions...read more
5 stars

RE:RE:RE:INTERESTING REPORT FROM ACC PRESENTATION ON evolocumab :

Many thanks Biotech77, as usual you have cleared these questions up for me. Thanks,jk  rate and reply
5 stars

RE:RE:INTERESTING REPORT FROM ACC PRESENTATION ON evolocumab :

JK, 1. Yes. LDL can be brought down too low. LDL is a primary lipid/ cholesterol transporter to cells. Unmodified LDL is not bad. What is bad is modified (acetylated or oxidized LDL). This...read more
5 stars

RE:RE:RE:RE:RE:RE:NISSEN INTERVIEW DURING. THIS MONTHS ACC

Right on Sanfran!  rate and reply
4.5 stars

RE:RE:RE:RE:RE:RE:NISSEN INTERVIEW DURING. THIS MONTHS ACC

After all, it WOULD be very typical for a mangement team to make changes to a situation after expectations were missed.  That's good management, typically.   Figure out what went wrong and then...read more
4.5 stars

RE:RE:RE:RE:RE:NISSEN INTERVIEW DURING. THIS MONTHS ACC

JK:  I wouldn't be surprised to find a new chairman on the clinical steering commitee in the future.   If I am right about my hunch that a new clinic will run future studies (and note that WE have a...read more